Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has resulted in significant financial losses for investors [3][4]. Group 1: Legal Actions - Investors have until August 25, 2025, to file lead plaintiff applications in the ongoing securities class action lawsuits against Hims & Hers Health, Inc. for purchases made between April 29, 2025, and June 23, 2025 [1][2]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case filed being Sookdeo v. Hims & Hers Health, Inc. [5]. Group 2: Company Issues - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to deceptive marketing practices [4]. - Following the announcement of the partnership termination, Hims' share price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025, amid unusually high trading volume [4]. Group 3: Law Firm Background - Kahn Swick & Foti, LLC, the law firm handling the lawsuits, is recognized as one of the top boutique securities litigation firms in the U.S., serving both institutional and retail investors [5].

Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform, connecting users with licensed healthcare professionals in the U.S. and the U.K. [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Hims, stemming from allegations of providing potentially misleading business information to the investing public [1] - On April 29, 2025, Novo Nordisk announced it would sell its weight loss drug Wegovy through Hims' telehealth platform, but on June 23, 2025, Novo Nordisk terminated its partnership with Hims due to concerns about Hims' compliance with laws governing the sale and marketing of compounded drugs [4] - Following the termination of the partnership, Hims' stock price fell by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [4]

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating whether Hims & Hers violated federal securities laws by making false or misleading statements during the Class Period from April 29, 2025, to June 22, 2025 [1]. - Following the termination of a partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs, Hims & Hers' shares dropped over 34% on June 23, 2025 [2]. - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2]. Group 2: Legal Action - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other harmed investors [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Hims & Hers and cert ...

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims & Hers - The complaint states that Hims failed to disclose that its communication with Novo Nordisk would not ensure a long-term collaboration for access to Wegovy for its subscribers [4]. - It is alleged that Novo did not approve Hims' offerings of compounded semaglutide products, contradicting Hims' positive statements about the partnership [4]. - The lawsuit highlights that Hims misrepresented the availability of branded Wegovy alongside compounded semaglutide options, which could mislead investors about user choice and access [4].

Group 1 - Hims & Hers Health (NYSE: HIMS) experienced a significant stock decline following the termination of its telehealth partnership with Novo Nordisk (NVO) [1] - The abrupt end of the partnership occurred before it had a chance to fully commence, leading to immediate market reactions [1] - Despite the negative impact on stock price, the long-term business strategy of Hims & Hers Health remains largely unaffected by this development [1]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during a defined class period [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [2]. - Investors are encouraged to contact the Schall Law Firm before August 25, 2025, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Hims & Hers made false and misleading statements regarding its marketing practices, particularly in relation to the promotion of products that could jeopardize patient safety [4]. - The company faced the risk of having its partnership with Novo Nordisk terminated due to these deceptive marketing activities [4]. - The misleading public statements resulted in financial damages to investors once the truth about the company's practices was revealed [4].

RADNOR, Pa., June 30, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25 ...

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...